Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.
Mantadakis
Elpis
E
Amoiridis
George
G
Kondi
Anna
A
Kalmanti
Maria
M
D000328:Adult; D000935:Antifungal Agents / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003711:Demyelinating Diseases / Q000139:chemically induced / Q000503:physiopathology; D004576:Electromyography; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy / Q000209:etiology; D008297:Male; D009431:Neural Conduction / Q000187:drug effects; D020258:Neurotoxicity Syndromes / Q000209:etiology / Q000503:physiopathology*; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000503:physiopathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D014230:Triazoles / Q000009:adverse effects*; D014750:Vincristine / Q000009:adverse effects*
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D014230:Triazoles; D014750:Vincristine; C101425:posaconazole; D011241:Prednisone